Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular Lymphoma

Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma (FL). There is no clear way to distinguish which patients will do poorly after treatment, and there’s also no biomarkers to determine the response, says Casulo. With a plethora of options available, a physician might select therapy based on when the patient recurs; if a patient recurred early, those patients can be treated more aggressively, but an older patient might need to be considered for a more gentle approach. For patients who have standard relapsed/refractory FL, there is no clear way to say which treatment may be more efficacious in a specific patient, Casulo concludes. This is due to a lack of predictors to response, which is a huge unmet need in this space. For more resources and information regarding anticancer targeted therapies in follicular lymphoma: http://targetedonc.com/resource-cente...